GlaxoSmithKline Plc (GSK)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014263)
◆英語タイトル:GlaxoSmithKline Plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014263
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:571
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cancer, cardiovascular, HIV and infectious diseases, respiratory, immuno-inflammation and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases. GSK’s vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups. GSK is headquartered in Brentford, Middlesex, the UK.

GlaxoSmithKline Plc (GSK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

List of Tables
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 18
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 19
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 20
GlaxoSmithKline Plc, Deals By Therapy Area, 2011 to YTD 2017 21
GlaxoSmithKline Plc, Medical Devices Deals, 2011 to YTD 2017 23
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 24
Pfizer May Sell Consumer Healthcare Business 48
Merck Plans to Sell its Consumer Health Business 49
ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 51
ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 52
GlaxoSmithKline Acquires Consumer Healthcare Pharma Business of Novartis 53
GlaxoSmithKline Acquires Vaccines Business of Novartis for up to USD7.1 Billion 55
Novartis India to Sell Its OTC Division to GlaxoSmithKline Consumer 57
ViiV Healthcare Acquires Integrase Inhibitor Portfolio Of Shionogi 58
Stiefel Labs Acquires WBI-1001 From Welichem Biotech For US$34 Million 59
Palleon Pharma Raises USD47.6 Million in Series A Financing 60
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 61
Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 63
TP Therapeutics Raises USD45 Million in Series C Financing 65
Pulmocide Raises USD30.4 Million in Series B Financing 66
Spero Therapeutics Raises USD51.7 Million in Series C Financing 68
Tioma Therapeutics Raises USD86 Million in Series A Financing 70
Second Genome Raises USD8.4 Million in Extended Series B Financing 71
Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 72
PDI Therapeutics to Raise up to USD10 Million in Series A Venture Financing 73
Mission Therapeutics Raises USD85.7 Million in Financing Round 74
Spero Therapeutics to Raise USD30 Million in Series B Preferred Financing 75
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 76
Navitor Pharma Raises USD33 Million in Series B Financing 78
Constellation Pharma Raises USD55 Million Financing 80
True North Therapeutics Raises USD40 Million in Series C Financing 82
Iron Horse Therapeutics to Raise up to USD10 Million in Series A Venture Financing 84
Iron Horse Therapeutics to Raise up to USD10 Million in Series A Venture Financing 85
Atreca Raises USD56 Million in Series A Financing 86
Decibel Therapeutics Raises USD52 Million in Series A Financing Round 87
Asceneuron Raises USD30.6 Million in Series A Financing 88
Gladius Pharma Raises USD3.3 Million in Series A Financing 90
Atopix Therapeutics Raises Additional Funds through Venture Financing 91
Adrenergics Raises up to USD10 Million in Series A Financing 92
CadheRx Therapeutics Raises up to USD10 Million in Series A Financing 93
Calporta Therapeutics Raises up to USD10 Million in Series A Financing 94
Spero Therapeutics Raises USD30 Million in Extended Series A Financing 95
PsiOxus Therapeutics Raises USD39.2 Million in Series C Financing 96
CRISPR Therapeutics Raises Additional USD35 Million in Series A Financing 98
CRISPR Therapeutics Raises USD29 Million in Series B Financing 100
ZappRx Raises USD5.6 Million in Series A Financing 102
Thrasos Therapeutics Raises USD21 Million in Series D Financing 103
Nimbus Therapeutics Raises USD43 Million in Series B Financing 105
Macrolide Pharma Raises USD22 Million in Series A Financing 106
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 107
Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 109
Atopix Therapeutics Raises Funds through Extended Series A Financing 110
Silarus Therapeutics to Raise up to USD10 Million in Series A Venture Financing 111
Thyritope Biosciences to Raise up to USD10 Million in Series A Venture Financing 112
Atox Bio Raises up to USD23 Million in Series E Venture Financing 113
Navitor Pharma Raises USD24 Million in Series A Financing 114
True North Therapeutics Raises USD22 Million in Series A Venture Financing 116
Principia Biopharma Raises US$50 Million In Series B Venture Financing 117
Spero Therapeutics Raises USD3 Million in Series A Venture Financing 119
Alios BioPharma Raises US$41 Million In Series B Venture Financing 120
RuiYi Raises US$15 Million In Series B Financing 121
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 123
VHsquared Secures Series A Funding Round 124
Sitari Pharma Raises US$10 Million In Series A Financing 125
Mission Therapeutics Raises US$32 Million In Series B Financing 126
Aileron Therapeutics Raises US$30 Million In Series E Financing 127
F-Star Alpha Raises US$13 Million In Series A Financing 129
iPierian Raises US$30 Million In Series A Venture Financing 130
Effector Therapeutics Raises US$45 Million In Series A Financing 132
Progenitor Labs Raises US$5.8 Million In Seed Financing 134
Aileron Raises US$12 Million In Extended Series D Financing 135
NeRRe Therapeutics Raises US$18 Million In Series A Financing 137
River Vision Development Raises US$17 Million In Series A Financing 138
Bicycle Therapeutics Raises US$6 Million In Venture Financing 139
Applied Genetic Technologies Raises US$37.5 Million In Series B Financing 141
HTG Molecular Diagnostics Raises US$7.5 Million In Series E Financing 142
Thrasos Therapeutics Raises US$35 Million In Venture Financing 143
SR One Plans To Invest In Biotechnology Company 145
Genocea Biosciences Raises US$30 Million In Series C Financing 146
Principia Biopharma Raises Additional US$13 Million In Series A Financing 148
PsiOxus Therapeutics Raises Additional US$34 Million In Series B Financing 150
RaNA Therapeutics Raises Additional US$18 Million In Series A Financing 152
Mission Therapeutics Raises US$10 Million In Series A Financing 154
Nimbus Discovery Secures US$24 Million In Series A Financing 155
High Throughput Genomics Secures US$0.5 Million In Second Closing Of Series D Venture Round 156
Constellation Pharma Secures Additional US$15 Million In Series B Financing 157
f-star Secures US$21.7 Million In Financing Round 159
Principia Biopharma Raises US$12 Million In First Tranche Of Series A Financing 161
Genocea Biosciences Secures US$35 Million In Series B Venture Financing 162
Plasticell Enters into Agreement with GlaxoSmithKline 164
AbCellera Biologics Enters into Research Partnership with GlaxosmithKline 165
Oklahoma Medical Research Foundation Enters into Agreement with GlaxoSmithKline 166
Exscientia Enters into Partnership with GlaxoSmithKline (GSK) 167
Aseptic Technologies Enters into Agreement with MedCision 168
Warp Drive Bio Enters to Agreement with GlaxoSmithKline 169
Telo Therapeutics Enters into Research Agreement with GlaxoSmithKline 170
Puridify Enters into Agreement with GlaxoSmithKline 171
Fimbrion Therapeutics Enters into Co-Development Agreement with GlaxoSmithKline 172
GlaxoSmithKline Enters into Co-Development Agreement with University of Leicester 173
GlaxoSmithKline Forms Joint Venture with Avalon Ventures 174
GlaxoSmithKline Enters into Agreement with Miltenyi Biotec 175
VBI Vaccines Enters into Research Agreement with GlaxoSmithKline Biologicals 176
Valneva Enters into R&D Agreement with GlaxoSmithKline 177
ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 178
GlaxoSmithKline Enters into Research Agreement with NIAID 179
GlaxoSmithKline Forms Iron Horse Therapeutics with Avalon Ventures 180
GlaxoSmithKline Partners with Merck 181
Pfizer Enters into Agreement with GlaxoSmithKline 182
UC San Francisco Enters into Research Agreement with GlaxoSmithKline 183
MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 184
GlaxoSmithKline Enters into Partnership with Francis Crick Institute 185
University of North Carolina Forms Joint Venture with GlaxoSmithKline 186
Cold Spring Harbor Labs Enters into Co-Development Agreement with GlaxoSmithKline 187
MolMed Enters into Agreement with GlaxoSmithKline 188
Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 189
GlaxoSmithKline Expands its Partnership with Adimab 191
Dynavax Technologies Expands Co-Development Agreement With GlaxoSmithKline 192
GlaxoSmithKline, Monash University, McCall MacBain Foundation, Grand Challenges Canada and Planet Wheeler Foundation Enter into Co-Development Agreement 194
ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 195
Bioversys Enters into Agreement with GlaxoSmithKline and University of Lille 196
Metabolon Enters Into Agreement With GlaxoSmithKline For Metabolomic Profiling Services 197
GlaxoSmithKline Enters Into Agreement With University of Texas MD Anderson Cancer Center For Immunotherapy Drugs 198
BioRap Enters into Agreement with GlaxoSmithKline 199
BioRap Technologies Enters into Co-Development Agreement with GlaxoSmithKline 200
University Of Edinburgh Enters Into Agreement With GlaxoSmithKline To Develop Medicines For Liver Disease 201
GlaxoSmithKline Enters into Partnership with Yale University 202
Santaris Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For RNA-Targeted Medicines 203
ViiV Healthcare And Shionogi Enter Into Co-Promotion Agreement For Dolutegravir 204
GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 205
GSK Enters Into Agreement With Bill & Melinda Gates Foundation To Discover Vaccines 206
GlaxoSmithKline Plans To Partner With Chinese Companies 207
GlaxoSmithKline Enters Into Co-Development Agreement With Institute of Chemical Engineering And Sciences 208
Eddingpharm Enters Into Distribution Agreement With GlaxoSmithKline For Tykerb 209
AB-Biotics Enters Into Co-Promotion Agreement With GlaxoSmithKline For Neurofarmagen 210
Proteologics And GlaxoSmithKline Extend Their Research Agreement 211
Hospital for Sick Children Enters Into Research Agreement With GlaxoSmithKline To Discover Treatment For Cystic Fibrosis 212
Vanderbilt University Enters Into Research Agreement With GlaxoSmithKline For Obesity Drug 213
GlaxoSmithKline To Form Joint Venture With Biological E 214
Priaxon Enters Into Co-Development Agreement With GlaxoSmithKline For Small Molecule Modulators Of PPIs 215
Chroma Therapeutics Expands Co-Development Agreement With GlaxoSmithKline 216
GlycoVaxyn Enters Into Co-Development Agreement With GlaxoSmithKline For Bacterial Vaccines 217
Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 218
GlaxoSmithKline Enters Into Agreement With Imagine Institute To Discover New Drugs For Netherton Syndrome 219
Chiromics Enters Into Drug Discovery Agreement With GlaxoSmithKline 220
Aeras Enters Into R&D Agreement With GlaxoSmithKline Vaccines To Develop Tuberculosis Vaccine 221
GlaxoSmithKline Enters Into Co-Development Agreement With University of Cambridge 222
PeptiDream Enters into Drug Discovery Agreement with GlaxoSmithKline 223
Daiichi Sankyo And GlaxoSmithKline Form Joint Venture In Japan 224
Auxilium Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline For Testim 1% 225
Desitin Arzneimittel Enters Into Co-Promotion Agreement With GlaxoSmithKline For Elontril 226
GlaxoSmithKline Enters Into Co-Development Agreement With Yale University 227
Five Prime Therapeutics Enters Into Co-Development Agreement With GlaxoSmithKline 228
Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 230
GlaxoSmithKline Enters Into Co-Development Agreement With University of Dundee 231
Angiochem Enters Into Co-Development Agreement With GlaxoSmithKline 232
GlaxoSmithKline Enters Into Co-Marketing Agreement With Coland Holdings 233
GlaxoSmithKline Enters Into Co-Development Agreement With Sienna Biotec 234
Eddingpharm Enters Distribution Agreement With GlaxoSmithKline For Relafen 235
ProteoTech Enters Into Co-Development Agreement With GlaxoSmithKline China 236
Eddingpharm Enters Into Distribution Agreement With GlaxoSmithKline For Hycamtin 237
GlaxoSmithKline Enters Into Co-Development Agreement With University of Dundee For Huntington's Disease 238
Signum Biosciences Enters Into Co-Development Agreement With GlaxoSmithKline 239
Life Technologies Enters Into Co-Development Agreement With GlaxoSmithKline Biologicals 240
GlaxoSmithKline Enters Into Co-Development Agreement With The University Of Edinburgh 241
University Of Edinburgh Enters Into Agreement With GlaxoSmithKline To Develop Acute Pancreatitis Treatments 242
Dong-A Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline Korea 243
Anacor Pharma Amends And Expands Research Collaboration With GlaxoSmithKline 244
GlaxoSmithKline Enters Into Co-Marketing Agreement With Sinopharm 246
4-Antibody Enters Into Co-Development Agreement With Human Genome Sciences 247
Unigene Labs Enters Into Co-Development Agreement With GlaxoSmithKline 248
GlaxoSmithKline Enters Into Co-Promotion Agreement With Daiichi Sankyo 249
GlaxoSmithKline Enters Into Co-Development Agreement With University of Dundee 250
PATH Malaria Vaccine Initiative Enters Into An Agreement With Crucell And GlaxoSmithKline 251
GlaxoSmithKline, AstraZeneca And The University Of Manchester Form Joint Venture 252
Imperial College London, King's College London, University College London, Medical Research Council And GSK Form Joint Venture 254
Cureveda Enters into Research Agreement with GlaxoSmithKline 256
GlaxoSmithKline Enters Into Co-Development Agreement With McGill University 257
GlaxoSmithKline Enters Into Co-Marketing Agreement With Dong-A Pharma For Seretide, Avamys And Vaxar 258
Epizyme Enters Into Co-Development Agreement With GlaxoSmithKline 259
DENTSPLY International Enters Into Co-Development Agreement With GlaxoSmithKline 260
GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 261
GlaxoSmithKline Enters into Licensing Agreement with Adaptimmune Therapeutics 262
Zai Lab Enters into Licensing agreement with GlaxoSmithKline 263
Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 264
Ionis Pharmaceuticals Enters Into Licensing Agreement with Glaxo Group and GlaxoSmithKline 265
Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 266
GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 267
Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 268
Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 269
GlaxoSmithKline Exercises Licensing Agreement with Adaptimmune 270
MorphoSys Enters Into Licensing Agreement With GSK For MOR103 272
NeRRe Therapeutics Receives Neurokinin Receptor Antagonists from GlaxoSmithKline 274
GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland 275
GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 276
Oxford BioMedica Exercises Option for Licensing Agreement with GlaxoSmithKline 277
GlaxoSmithKline Exercises Option for Licensing Agreement with Five Prime Therapeutics 278
Codexis Enters into Licensing Agreement with GlaxoSmithKline for CodeEvolver Protein Engineering Platform 279
GlaxoSmithKline Enters into Licensing Agreement with Pelago Bioscience for CETSA 281
Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 282
Medicines Patent Pool Extends Licensing Agreement with ViiV Healthcare 283
GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 284
GlaxoSmithKline Enters Into Licensing Agreement With Adimab 285
Immunocore Enters Into Licensing Agreement With GSK For ImmTACs 286
ViiV Healthcare Enters Into Licensing Agreement With Medicines Patent Pool For Epzicom 287
GlycoVaxyn Enters Into Licensing Agreement With Janssen Pharma For Bacterial Vaccine 288
GlaxoSmithKline Enters Into Licensing Agreement With University of Texas MD Anderson Cancer Center For Antibodies 289
GlaxoSmithKline Enters Into Licensing Agreement With Alacris Theranostics For ModCell System 290
ViiV Healthcare Announces Licensing Agreement For Celsentri 291
Agenus Amends Licensing Agreement With GlaxoSmithKline For QS-21 Stimulon 292
GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos 293
GlaxoSmithKline Enters into Licensing Agreement with Janssen Biologics 294
Covis Pharma Enters Into Licensing Agreement With GlaxoSmithKline 295
Alnylam Pharma Enters Into Licensing Agreement With GlaxoSmithKline 296
Theravance Expands Licensing Agreement With GlaxoSmithKline 297
NPS Pharma Enters Into Licensing Agreement With GlaxoSmithKline For SB-423557, SB-423562 And Ronacaleret 298
Arecor Enters Into Licensing Agreement With GlaxoSmithKline 299
Vivalis Enters Into Research License Agreement With Okairos 300
Human Genome Sciences Enters Into Licensing Agreement With FivePrime Therapeutics For FP-1039 301
AFFiRiS Extends Licensing Agreement With GlaxoSmithKline 303
GlaxoSmithKline Enters Into Licensing Agreement With Menarini For Bilastine 304
Immutep Enters Into Licensing Agreement With GlaxoSmithKline For ImmuTune IMP731 305
Aspen Pharmacare Raises USD624 Million in Private Placement of Shares 306
Theravance Biopharma Raises USD23 Million in Private Placement of Shares 308
Amicus Therapeutics Completes Private Placement Of Securities For US$15 Million 309
Theravance Completes Private Placement Of Shares For US$213 Million 310
ChemoCentryx Announces Private Placement For US$7 Million 311
GlaxoSmithKline Raises USD1,428 Million in Public Offering of Bonds Due 2020 312
GlaxoSmithKline Raises USD832.8 Million in Public Offering of Bonds Due 2026 313
GlaxoSmithKline Completes Public Offering Of 0.75% Senior Notes Due 2015 For US$1,000 Million 314
GlaxoSmithKline Completes Public Offering Of 1.5% Senior Notes Due 2017 For US$2,000 Million 315
GlaxoSmithKline Completes Public Offering Of 2.85% Senior Notes Due 2022 For US$2,000 Million 316
Human Genome Completes Underwritten Public Offering Of 3% Notes Due 2018 For US$494.5 Million 317
GlaxoSmithKline Plans to Sell its Ulverston Plant 319
Emergent Biosolutions Acquires Raxibacumab from GSK 320
Avara Pharma to Acquire Consumer Healthcare Manufacturing Facility from GlaxoSmithKline 322
GlaxoSmithKline Plans to Sell its Non-Core brands 323
Aspen Pharmacare Acquires Anaesthesia Portfolio from GlaxoSmithKline 324
Oncodesign Acquires Francois Hyafil Research Centre from GlaxoSmithKline 325
Mayne Pharma Acquires Rights to Foam Assets from GlaxoSmithKline for USD50 Million 326
Novartis Pharma Acquires Rights to Ofatumumab for Auto-Immune Indications from GlaxoSmithKline for up to USD1 Billion 327
Almirall Acquires Rights to Veltin and Altabax from Stiefel 328
Interbrands Acquires Europharm from GSK 329
Pfizer Acquires Nimenrix and Mencevax from GlaxoSmithKline for USD130 Million 330
Sun Pharma Acquires Opiates Business in Australia from GlaxoSmithKline 331
Perrigo Acquires OTC Brands Portfolio from GlaxoSmithKline Consumer Healthcare for USD226 Million 332
Novartis Acquires Cancer Drugs Business of GlaxoSmithKline 333
Roivant to Acquire SB742457 from GlaxoSmithKline 335
Dr Reddy's Labs Acquires Habitrol from Novartis Consumer Health 336
Axovant Sciences Acquires Rights to RVT-101 from Glaxo Group and GlaxoSmithKline Intellectual 337
Pernix Therapeutics Completes Acquisition of Treximet Tablets For Migraine From GlaxoSmithKline 338
Suntory Beverage Acquires Lucozade and Ribena Brands from GlaxoSmithKline for USD2.1 Billion 340
Aspen Pharmacare Completes Acquisition of Thrombosis Brands And Manufacturing Facility from GlaxoSmithKline for USD1.13 Billion 342
Aqua Pharma Acquires US Rights To Verdeso Foam From Stiefel 344
Renaissance Acquisition To Acquire Six Dermatology And Three Anti-Viral Products From GSK 345
Mayne Pharma Acquires Kapanol from GlaxoSmithKline for USD15 Million 347
Aspen Completes Acquisition Of Non-Core Australian Drugs From GlaxoSmithKline For US$257 Million 348
Merz Pharma Acquires Onmel From Stiefel Labs 350
Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 351
Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For US$614 Million 352
Aspen Pharmacare Completes Acquisition Of Non-Core OTC Brands From GlaxoSmithKline For US$263 Million 354
Prestige Brands Completes Acquisition Of 17 OTC Healthcare Brands From GlaxoSmithKline For US$660 Million 356
Adolor Reacquires Rights Of ENTEREG From GlaxoSmithKline 359
Dr. Reddy’s Labs Completes Acquisition Of Oral Penicillin Facility And Product Portfolio From GlaxoSmithKline 360
Biovail Labs Acquires US And Canadian Rights To Zovirax From GlaxoSmithKline 362
AltheRx Acquires Solabegron From GlaxoSmithKline 363
Capsugel Acquires FlexTab Technology From GlaxoSmithKline 364
Aqua Pharma Acquires XOLEGEL, Topical Treatment Of Seborrheic Dermatitis, From Stiefel Labs 365
Recordati Acquires Rights To Procto-Glyvenol From Novartis 366
Meda Acquires Two Additional OTC Products In US From GlaxoSmithKline 367
MediPal Plans to Acquire 22% Stake in JCR Pharma from Glaxo Group for USD189.7 Million 368
United Therapeutics May Sell Itself 369
GlaxoSmithKline May Acquire Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD10.3 Billion 370
Pacific Biosciences May Sell Itself 371
GlaxoSmithKline Acquires Remaining Stake in GlycoVaxyn for USD190 Million 372
GlaxoSmithKline to Acquire 25% Stake in Aspen Japan 374
AstraZeneca May Acquire Ariad Pharma 375
GlaxoSmithKline Acquires Remaining 30% Stake In Consumer Healthcare Business For US$40.6 Million 377
GlaxoSmithKline Completes Acquisition Of Additional 24.3% Stake In Indian Arm GlaxoSmithKline Pharma For US$1.03 Billion 378
GlaxoSmithKline Completes Sale Of 6.19% Stake In Aspen Pharmacare For US$696.5 Million 380
Ipsen Acquires Syntaxin, Life Sciences Company, For US$206 Million 382
GlaxoSmithKline Acquires Okairos For US$325 Million 384
GlaxoSmithKline And Avalon Ventures To Invest US$495 Million In 10 Drug Discovery Startups 386
GSK Increases Stake In Indian Arm GlaxoSmithKline Consumer Healthcare For US$864 Million 387
Takeda America Completes Acquisition Of LigoCyte Pharma For US$60 Million 389
GlaxoSmithKline Acquires Remaining 80.02% Stake In Cellzome, Proteomics Company, For US$99 Million 391
GlaxoSmithKline Completes Acquisition Of Human Genome Sciences For US$3.6 Billion 393
GlaxoSmithKline Plans To Acquire BioMarin Pharma 395
GlaxoSmithKline Plans To Acquire Turkey-based Pharma Company 396
GlaxoSmithKline Plans To Acquire Indian Pharma Companies 397
GlaxoSmithKline Completes Acquisition Of Remaining 51% JV Stake In Shenzhen GSK-Neptunus Biologicals For US$39 Million 398
SuperGen Completes Acquisition Of Astex Therapeutics 399
GlaxoSmithKline Plc, Key Competitors 402
GlaxoSmithKline Plc, Key Employees 403
GlaxoSmithKline Plc, Other Locations 404
GlaxoSmithKline Plc, Subsidiaries 404
GlaxoSmithKline Plc, Joint Venture 416

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ GlaxoSmithKline Plc (GSK)-製薬・医療分野:企業M&A・提携分析(GlaxoSmithKline Plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆